Alert detail

FDA Approval: ANZUPGO (DELGOCITINIB) — Type 1 - New Molecular Entity

Policy ID: FDA-NDA219155Specialty: DermatologyAdded: 7/8/2026Effective: July 23, 2025federal register

Low

What changed

Topical JAK inhibitor cream billed under Part D pharmacy benefit.

Who’s affected: Dermatology billing teams · Effective: July 23, 2025

Primary source: View the official CMS/MAC document ↗

Get the action steps and full analysis

Subscribers get the recommended action (“what to do”), the full AI analysis, the LCD revision comparison, and related alerts across your specialty and jurisdiction.

View subscription plans Create a free account

Audit documentation

Building an audit file?

The Tripwire Audit Pack exports 12 months of Dermatology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Dermatology audit pack — $349One-time purchase · not a subscription

Not ready to subscribe?

Get the free weekly reimbursement brief for Dermatology— the week’s changes and deadlines, delivered to your inbox. No account required.